| Public | NASDAQ:HZNP |
| Date | 7/11 |
| Website | horizonpharma.com |
| Category | BioTech |
| Phone | 224-383-3000 |
| Employees | |
| Founded | 2005 |
| Description | biopharmaceutical company |
| TOTAL | $51.1M |
| VENTURE FUNDING TOTAL | $51.1M |
| Series A, 10/05 | $6.05M |
| Series B, 11/06 | $15M |
| Series C, 7/07 | $30M |
Horizon Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company’s product candidates include HZT-501, a proprietary fixed dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine.
Horizon Therapeutics, Inc. was founded in 2005 and is headquartered in Northbrook, Illinois with an additional office in Palo Alto, California. As of April 1, 2010, Horizon Therapeutics, Inc. operates as a subsidary of Horizon Pharma, Inc.
